Matteo Levisetti - 21 Mar 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Matteo Levisetti by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
21 Mar 2025
Transactions value $
$0
Form type
4
Filing time
25 Mar 2025, 16:00:03 UTC
Previous filing
07 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +250,000 $0 250,000 21 Mar 2025 Common Stock 250,000 $0.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.